Activity and tolerability of combination of trastuzumab deruxtecan with olaparib in preclinical HER2+and HER2-low breast cancer models

被引：2
|
作者：
Proia, Theresa
Wallez, Yann
Bashi, Azadeh Cheraghchi
Wilson, Zena
Randle, Suzanne
Anderton, Mark
Carroll, Danielle
Rasheed, Zeshaan
Pease, J. Elizabeth
Leo, Elisabetta
Mettetal, Jerome
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P2-13-18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-13-18
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Activity and tolerability of combination of trastuzumab deruxtecan with the pan-AKT inhibitor capivasertib in preclinical HER2+and HER2-low breast cancer models
    Bashi, Azadeh Cheraghchi
    Proia, Theresa
    Randle, Suzanne
    Anderton, Mark
    Rasheed, Zeshaan
    Pease, J. Elizabeth
    Barry, Simon
    Carroll, Danielle
    Mettetal, Jerome
    CANCER RESEARCH, 2022, 82 (04)
  • [2] Safety and Efficacy of Trastuzumab Deruxtecan for Metastatic HER2+and HER2-low Breast Cancer
    Qureshi, Zaheer
    Altaf, Faryal
    Jamil, Abdur
    Siddique, Rimsha
    Fatima, Eeshal
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (11): : 535 - 541
  • [3] Trastuzumab Deruxtecan in HER2-Low Breast Cancer
    Carroll, Hailey K.
    Higgins, Michaela J.
    O'Reilly, Seamus
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (12): : 1144 - 1144
  • [4] TRASTUZUMAB DERUXTECAN IS EFFECTIVE IN HER2-LOW BREAST CANCER
    不详
    CANCER DISCOVERY, 2020, 10 (04) : 488 - 488
  • [5] Trastuzumab and Deruxtecan Combination for Survival Benefit in Patients with HER2-low Breast Cancer
    Lichert, Frank
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (10)
  • [6] Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
    Modi, Shanu
    Jacot, William
    Yamashita, Toshinari
    Sohn, Joohyuk
    Vidal, Maria
    Tokunaga, Eriko
    Tsurutani, Junji
    Ueno, Naoto T.
    Prat, Aleix
    Chae, Yee Soo
    Lee, Keun Seok
    Niikura, Naoki
    Park, Yeon Hee
    Xu, Binghe
    Wang, Xiaojia
    Gil-Gil, Miguel
    Li, Wei
    Pierga, Jean-Yves
    Im, Seock-Ah
    Moore, Halle C. F.
    Rugo, Hope S.
    Yerushalmi, Rinat
    Zagouri, Flora
    Gombos, Andrea
    Kim, Sung-Bae
    Liu, Qiang
    Luo, Ting
    Saura, Cristina
    Schmid, Peter
    Sun, Tao
    Gambhire, Dhiraj
    Yung, Lotus
    Wang, Yibin
    Singh, Jasmeet
    Vitazka, Patrik
    Meinhardt, Gerold
    Harbeck, Nadia
    Cameron, David A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (01): : 9 - 20
  • [7] Safety and efficacy of trastuzumab deruxtecan for metastatic HER2+and HER2-low breast cancer: An updated systematic review and meta-analysis of clinical trials
    Qureshi, Zaheer
    Altaf, Faryal
    Jamil, Abdur
    Siddique, Rimsha
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with carcinomatosis
    Batista, Marta Vaz
    Perez-Garcia, Jose Manuel
    Garrigos, Laia
    Garcia-Saenz, Jose Angel
    Cortez, Patricia
    Racca, Fabricio
    Blanch, Salvador
    Ruiz-Borrego, Manuel
    Fernandez-Ortega, Adela
    Fernandez Abad, Maria
    Iranzo, Vega
    Gion, Maria
    Martrat, Griselda
    Alcala-Lopez, Daniel
    Perez-Escuredo, Jhudit
    Sampayo-Cordero, Miguel
    Llombart-Cussac, Antonio
    Braga, Sofia
    Cortes, Javier
    MED, 2025, 6 (01):
  • [9] The Real-World Clinical Outcomes of Heavily Pretreated HER2+and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre
    Lazaratos, Anna-Maria
    Dankner, Matthew
    Hamouda, Aalya
    Labidi, Soumaya
    Cohen, Victor
    Panasci, Lawrence
    Friedmann, Jennifer E.
    Patenaude, Francois
    Ferrario, Cristiano
    Basik, Mark
    Rose, April A. N.
    Fallah, Parvaneh
    CURRENT ONCOLOGY, 2025, 32 (01)
  • [10] Concurrent Use of Trastuzumab Deruxtecan and Radiation Therapy in HER2-positive and HER2-low Metastatic Breast Cancer
    Bouziane, Jihane
    Loap, Pierre
    Cao, Kim
    Allali, Sofiane
    Gounane, Yacine
    Loganadane, Gokoulakrichenane
    Escalup, Laurence
    Pierga, Jean-Yves
    Kirova, Youlia
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (12): : 580 - 584
12345